抗Flt-1抗体(Anti-Flt-1, Phosphorylated, Rabbit-Poly antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	Phosphopeptide containing human VEGF R1/Flt-1 Y1213 site
Source	Polyclonal Rabbit IgG
Purification	Antigen Affinity-purified
Specificity	Detects human VEGF R1/Flt-1 when phosphorylated at Y1213.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	1 µg/mL	See below

Western Blot

Detection of Human Phospho-VEGF R1/Flt‑1 (Y1213) by Western Blot. Western blot shows lysates of HUVEC human umbilical vein endothelial cell untreated (-) or treated (+) with 100 μM pervanadate (PV) for 10 minutes. PVDF membrane was probed with 1 µg/mL of Rabbit Anti-Human Phospho-VEGF R1/Flt‑1 (Y1213) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4170), followed by HRP-conjugated Anti‑Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-VEGF R1/Flt‑1 (Y1213) at approximately 180 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

目次に戻る

Related Product & Information

Long Name	Vascular Endothelial Growth Factor Receptor 1
Background	VEGF R1/Flt-1
background_content	Background: VEGF R1/Flt-1 VEGF R1, also known as Flt-1, is a receptor tyrosine kinase that contains seven Ig-like repeats in its extracellular domain, a single transmembrane region, and a kinase domain in the intracellular region. Ligand binding induces autophosphorylation on multiple intracellular tyrosine residues. Y1213 is a major binding site for PI3K, Nck, and SHP-2.

目次に戻る

Citations

1. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
   Authors: MG Atzori, L Tentori, F Ruffini, C Ceci, L Lisi, E Bonanno, M Scimeca, E Eskilsson, T Daubon, H Miletic, L Ricci Viti, R Pallini, P Navarra, R Bjerkvig, S D'Atri, PM Lacal, G Graziani
   J. Exp. Clin. Cancer Res., 2017;36(1):106.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


2. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibition.
   Authors: Huang H, He J, Johnson D, Wei Y, Liu Y, Wang S, Lutty G, Duh E, Semba R
   Diabetes, 2015;64(1):200-12.
   Species: Mouse
   Sample Type: Whole Tissue
   Application: IF


3. BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
   Authors: Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi R, Xu W, Karakousis G, Gangadhar T, Schuchter L, Lieu M, Khare S, Halloran M, Herlyn M, Kaufman R
   Clin Cancer Res, 2015;21(7):1652-64.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


4. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells.
   Authors: Attar-Schneider O, Drucker L, Zismanov V
   Lab. Invest., 2012;92(2):178-90.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


5. Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages.
   Authors: Meda C, Molla F, De Pizzol M
   J. Immunol., 2012;188(8):4081-92.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


6. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.
   Authors: Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, Stassen JM, Presta M, Ambati J, Ruvo M, De Falco S
   J. Biol. Chem., 2008;283(49):34250-9.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB

目次に戻る